# Louis Aledort

List of Publications by Year
in descending order



| 116 | 1,926 | 567281 15 | 265206 42 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 132 | 132 | 132 | 1645 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Definitions in Hemophilia. Thrombosis and Haemostasis, 2001, 85, 560-560. | 3.4 | 679 |
| 2 | Human Recombinant DNAâ€“Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A. New England Journal of Medicine, 1990, 323, 1800-1805. | 27.0 | 261 |
| 3 | A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood, 2014, 123, 3887-3894. | 1.4 | 112 |
| 4 | The Role of Platelet Activation and Inflammation in Early Brain Injury Following Subarachnoid Hemorrhage. Neurocritical Care, 2017, 26, 48-57. | 2.4 | 112 |
| 5 | Prophylactic Use of Factor VIII: an Economic Evaluation. Thrombosis and Haemostasis, 1998, 79, 932-937. | 3.4 | 88 |
| 6 | Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfusion, 2019, 17, 479-486. | 0.4 | 53 |
| 7 | The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. Journal of Thrombosis and Haemostasis, 2011, 9, 2229-2234. | 3.8 | 42 |
| 8 | Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. British Journal of Haematology, 1990, 76, 238-241. | 2.5 | 40 |
| 9 | Why should we care about quality of life in persons with haemophilia?. Haemophilia, 2012, 18, e154-7. | 2.1 | 34 |
| 10 | Factor VIII therapy for hemophilia A: current and future issues. Expert Review of Hematology, 2014, 7, 373-385. | 2.2 | 27 |
| 11 | Tertiary prophylaxis in adults: is there a rationale?. Haemophilia, 2012, 18, 722-728. | 2.1 | 26 |
| 12 | Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged â‰¥65Âyears with immune thrombocytopenia. Annals of Hematology, 2015, 94, 1973-1980. | 1.8 | 25 |
| 13 | Retrospective Matched Cohort Study of Immune Thrombocytopenic Purpura (ITP): Complications Related to Corticosteroid (CS) Use.. Blood, 2006, 108, 3295-3295. | 1.4 | 24 |
| 14 | Reproductive choices in hemophilic men and carriers. American Journal of Medical Genetics Part A, 1987, 26, 591-598. | 2.4 | 23 |
| 15 | Deaths Associated with Emicizumab in Patients with Hemophilia A. New England Journal of Medicine, 2019, 381, 1878-1879. | 27.0 | 20 |
| 16 | Inhibitors in Hemophilia B. , 0, , 97-100. | | 16 |
| 17 | Inhibitors to Factor VIIIâ€”Epidemiology and Treatment. , 0, , 64-70. | | 15 |
| 18 | Evaluating the safety of emicizumab in patients with hemophilia A. Expert Opinion on Drug Safety, 2018, 17, 1233-1237. | 2.4 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Current Concepts in Diagnosis and Management of Hemophilia. Hospital Practice (1995), 1982, 17, 77-92. | 1.0 | 14 |
| 20 | Treatment of Congenital Thrombotic Thrombocytopenia Purpura: A New Paradigm. Journal of Pediatric Hematology/Oncology, 2017, 39, 524-527. | 0.6 | 14 |
| 21 | Concurrence of von Willebrand's disease and hemophilia A: Implications for carrier detection and prevalence. American Journal of Medical Genetics Part A, 1986, 24, 83-94. | 2.4 | 13 |
| 22 | Why Thrombin Generation? From Bench to Bedside. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 2-3. | 0.3 | 12 |
| 23 | United States' factor XI-deficiency patients need a safer treatment. American Journal of Hematology, 2005, 80, 301-302. | 4.1 | 12 |
| 24 | Do hemophilia carriers bleed? Yes.. Blood, 2006, 108, 6-6. | 1.4 | 12 |
| 25 | An Open Label, Multi Center Study on the Efficacy and Safety of a Liquid, Ready-to-Use Intravenously Administered Anti-D Immunoglobulin in Patients with Chronic Immune Thrombocytopenic Purpura.. Blood, 2004, 104, 3943-3943. | 1.4 | 12 |
| 26 | Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis. Journal of Immunological Methods, 2018, 453, 11-19. | 1.4 | 11 |
| 27 | AIDS: An Update. Hospital Practice (1995), 1983, 18, 159-171. | 1.0 | 10 |
| 28 | Hepatitis A Virus Transmission by Blood Products in the United States. Vox Sanguinis, 1994, 67, 24-28. | 1.5 | 9 |
| 29 | The ongoing imperative for immune tolerance induction in inhibitor management. Haemophilia, 2019, 25, 183-186. | 2.1 | 9 |
| 30 | New Approaches to Management of Bleeding Disorders. Hospital Practice (1995), 1989, 24, 207-226. | 1.0 | 8 |
| 31 | Causes of death in haemophilia. Nature, 1995, 378, 124-124. | 27.8 | 8 |
| 32 | Inhibitors to Factor VIII/IX: Treatment of Inhibitorsâ€”Immune Tolerance Induction. , 0, , 74-79. | | 8 |
| 33 | Inhibitors of Factor VIII: Treatment of Acute Bleeds. , 0, , 80-85. | | 8 |
| 34 | Acquired hemophilia: We now see it with myeloproliferative neoplasms. American Journal of Hematology, 2011, 86, 329-330. | 4.1 | 8 |
| 35 | Managing incidentally diagnosed isolated factor VII deficiency perioperatively: a brief expert consensus report. Expert Review of Hematology, 2012, 5, 47-50. | 2.2 | 8 |
| 36 | Laboratory Assays in Hemophilia. , 0, , 235-241. | | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Some Aspects on the Management of Hemophilia. Thrombosis and Haemostasis, 1995, 74, 440-443. | 3.4 | 6 |
| 38 | Inhibitors to Factor VIIIâ€"Molecular Basis. , 0, , 59-63. | | 5 |
| 39 | Products used to Treat Hemophilia: Evolution of Treatment for Hemophilia A and B. , 0, , 131-135. | | 5 |
| 40 | Von Willebrand Disease: Epidemiology. , 0, , 265-271. | | 5 |
| 41 | Prophylaxis reâ€visited: The potential impact of novel factor and nonâ€factor therapies on prophylaxis. Haemophilia, 2018, 24, 845-848. | 2.1 | 5 |
| 42 | Adverse reactions related to rVIIa?. American Journal of Hematology, 2001, 67, 213-213. | 4.1 | 4 |
| 43 | Orthopedic Outcome Studies and Cost Issues. Seminars in Thrombosis and Hemostasis, 2003, 29, 055-060. | 2.7 | 4 |
| 44 | Inhibitors to Factor VIIIâ€"Mild and Moderate Hemophilia. , 0, , 71-73. | | 4 |
| 45 | Acquired Inhibitors to Factor VIII. , 0, , 86-90. | | 4 |
| 46 | The Neonate with Hemophilia. , 0, , 125-130. | | 4 |
| 47 | Synoviorthesis in Hemophilia. , 0, , 169-173. | | 4 |
| 48 | Pseudotumors in Patients with Hemophilia. , 0, , 174-176. | | 4 |
| 49 | Congenital Factor VII Deficiency. , 0, , 311-314. | | 4 |
| 50 | Quality of Life in Hemophilia. , 0, , 345-350. | | 4 |
| 51 | An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia. Haemophilia, 2017, 23, e447-e450. | 2.1 | 4 |
| 52 | Inhibitors to Coagulation: Can We Afford Immune Tolerance Induction Regimens?. Vox Sanguinis, 1996, 70, 77-78. | 1.5 | 3 |
| 53 | Treatment of Inhibitors in Hemophilia B. , 0, , 101-105. | | 3 |
| 54 | Products used to Treat Hemophilia: Recombinant Factor VIIa. , 0, , 147-152. | | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Transfusion Transmitted Disease: History of Epidemics (Focus on HIV). , 0, , 200-206. | | 3 |
| 56 | Gene Therapy for Hemophilia A. , 0, , 226-228. | | 3 |
| 57 | Standardization of Assays. , 0, , 242-248. | | 3 |
| 58 | An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia. Haemophilia, 2017, 23, e444-e447. | 2.1 | 3 |
| 59 | von Willebrand Disease: From the Bedside to Therapy. Thrombosis and Haemostasis, 1997, 78, 562-565. | 3.4 | 3 |
| 60 | Factor XI Deficiency. , 0, , 321-327. | | 2 |
| 61 | Hemophilia Bâ€"Molecular Basis. , 0, , 91-95. | | 2 |
| 62 | Joint Replacement. , 0, , 164-168. | | 2 |
| 63 | Magnetic Resonance Imaging/Joint Outcome Assessment. , 0, , 182-192. | | 2 |
| 64 | Obstetrics and Gynecology: Hemophilia. , 0, , 249-256. | | 2 |
| 65 | Treatment of Von Willebrand Disease: Desmopressin. , 0, , 285-288. | | 2 |
| 66 | Natural History of Inhibitor Development in Children with Severe Hemophilia a Treated with Factor VIII Products. , 0, , 34-38. | | 2 |
| 67 | The Economics of Hemophilia Treatments. , 0, , 351-358. | | 2 |
| 68 | Comprehensive Care and Delivery of Care: The Developed World. , 0, , 359-365. | | 2 |
| 69 | Comprehensive Care and Delivery of Care: The Developing World. , 0, , 366-370. | | 2 |
| 70 | The Clinical and Direct Medical Cost Burden of Splenectomy among Managed Care Patients with Chronic Immune Thrombocytopenic Purpura (ITP).. Blood, 2006, 108, 5536-5536. | 1.4 | 2 |
| 71 | Plug the hole. Blood, 2005, 105, 2621-2621. | 1.4 | 1 |
| 72 | Factor X and Factor X Deficiency. , 0, , 315-320. | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Care of the Child with Hemophilia. , 0, , 120-124. | | 1 |
| 74 | Products used to Treat Hemophilia: Dosing. , 0, , 153-157. | | 1 |
| 75 | Physiotherapy in the Management of Hemophilia. , 0, , 193-199. | | 1 |
| 76 | Transfusion Transmitted Disease: Hepatitis C Virus Infection and Liver Transplantation. , 0, , 207-213. | | 1 |
| 77 | Von Willebrand Disease: Biological Diagnosis. , 0, , 272-278. | | 1 |
| 78 | Treatment of Von Willebrand Disease: Therapeutic Concentrates. , 0, , 289-295. | | 1 |
| 79 | Factor V and Combined Factor V and VIII Deficiencies. , 0, , 306-310. | | 1 |
| 80 | Comprehensive Care and Delivery of Care: The Global Perspective. , 0, , 371-377. | | 1 |
| 81 | Prophylaxis. , 0, , 39-45. | | 1 |
| 82 | Inhibitors to Factor VIIIâ€"Immunology. , 0, , 53-58. | | 1 |
| 83 | Expert Review of Hematology:addressing the needs of a broad research field. Expert Review of Hematology, 2008, 1, 1-2. | 2.2 | 1 |
| 84 | Hemophilia lives: the impact of prophylaxis. Blood, 2008, 111, 1752-1753. | 1.4 | 1 |
| 85 | Hemophilia Lend-Lease Program in Italy Successfully Meets Albania Factor Needs. Blood, 2016, 128, 5916-5916. | 1.4 | 1 |
| 86 | Can costs of hemophilia products be curtailed? Not as we do business today!. Thrombosis and Haemostasis, 2002, 88, 541. | 3.4 | 1 |
| 87 | Medical necessity-a threat to treatment of chronic disease. Transfusion, 1995, 35, 712-712. | 1.6 | 0 |
| 88 | The above letter was sent to Dr. Aledort, who offered the following reply.. Transfusion, 2000, 40, 495-496. | 1.6 | 0 |
| 89 | Women and Von Willebrand Disease. , 0, , 296-301. | | 0 |
| 90 | Products Used to Treat Hemophilia: Plasma-Derived Coagulation Factor Concentrates. , 0, , 142-146. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Von Willebrand Disease: Molecular Aspects. , 0, , 257-264. | | 0 |
| 92 | Cellular Processing of Factors VIII and IX. , 0, , 5-12. | | 0 |
| 93 | Work-Up of a Bleeding Child. , 0, , 112-119. | | 0 |
| 94 | Products used to Treat Hemophilia: Recombinant Products. , 0, , 136-141. | | 0 |
| 95 | Products Used to Treat Hemophilia: Regulation. , 0, , 158-163. | | 0 |
| 96 | Work-Up of a Bleeding Adult. , 0, , 13-18. | | 0 |
| 97 | Gene Therapy: Introduction and Overview. , 0, , 214-219. | | 0 |
| 98 | Gene Therapy for Hemophilia B. , 0, , 220-225. | | 0 |
| 99 | Molecular Basis of Hemophilia A. , 0, , 19-26. | | 0 |
| 100 | Gene Therapy: Molecular Engineering of Factor VIII and Factor IX. , 0, , 229-234. | | 0 |
| 101 | Classification and Clinical Aspects of Von Willebrand Disease. , 0, , 279-284. | | 0 |
| 102 | Hemophilia A: Role of Factor VIII in Coagulation. , 0, , 27-33. | | 0 |
| 103 | Factor II. , 0, , 302-305. | | 0 |
| 104 | Factor XIII. , 0, , 328-331. | | 0 |
| 105 | Fibrinogen. , 0, , 332-337. | | 0 |
| 106 | Miscellaneous Rare Bleeding Disorders. , 0, , 338-344. | | 0 |
| 107 | Continuous Infusion of Coagulation Products in Hemophilia. , 0, , 46-52. | | 0 |
| 108 | Colour Plate. , 0, , 409-412. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Overview of Hemostasis. , 0, , 1-4. | | 0 |
| 110 | Why plasmaâ€derived factor VIII?. Haemophilia, 2019, 25, e183-e185. | 2.1 | 0 |
| 111 | In response to WFH guidelines for the management of haemophilia, 3<sup>rd</sup> edition: Is there a difference between extendedâ€halfâ€life FVIII products or not?. Haemophilia, 2021, 27, e762-e764. | 2.1 | 0 |
| 112 | Adverse Events (AEs): Are They Factored into Costs of Hemophilia Care?.. Blood, 2005, 106, 5550-5550. | 1.4 | 0 |
| 113 | Can Health Care Plans Afford Hemophilia Costs? Yes.. Blood, 2005, 106, 5551-5551. | 1.4 | 0 |
| 114 | Hemophilia Treatment - A Model for Appropriate Cost Control.. Blood, 2007, 110, 3942-3942. | 1.4 | 0 |
| 115 | Do we need a better test? Can thrombin generation be useful?. Psychophysiology, 2004, 3, 75-6. | 1.1 | 0 |
| 116 | Platelet bleeding disorders and approach to their management. Psychophysiology, 2005, 4, 85-7. | 1.1 | 0 |